TargetBeta
GUCY1B2
guanylate cyclase 1 soluble subunit beta 2 (pseudogene) · also GUCY1B2P, GC-SB2 · Soluble guanylate cyclases
3 programs in company-led studies act on GUCY1B2, from 3 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Nitroglycerinrule | MediQuest Therapeutics | phase 4 | 141 running | GUCY1A1, GUCY1A2, GUCY1B1 | ChEMBL |
| ataciguatrule | Sanofi | phase 3 | 31 running | GUCY1A1, GUCY1A2, GUCY1B1 | ChEMBL |
| praliciguatrule | Ironwood Pharmaceuticals | phase 2 | 81 running | GUCY1A1, GUCY1A2, GUCY1B1 | ChEMBL |
Conditions their studies are in
- Aortic Valve Stenosis, 1 program
- Connective Tissue Diseases, 1 program
- Coronary Artery Disease, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Erectile Dysfunction, 1 program
- Fissure in Ano, 1 program
- Glomerulosclerosis, Focal Segmental, 1 program
- Heart Failure, 1 program
- Intermittent Claudication, 1 program
- Pain, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 7, 2027Nitroglycerin · MediQuest Therapeutics · phase 4 · NCT07431294
- Jun 2027praliciguat · Ironwood Pharmaceuticals · phase 2 · NCT07268638
- Aug 31, 2028ataciguat · Sanofi · phase 3 · NCT07001800
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.